Showing results (1-10 of 529) with videos related to
Sort By:
Pageof 53
Cell Signaling|January 13, 2025
Potential biomarkers for MCL1 inhibitor sensitivityLei Duan, Carl G MakiTranslational Cancer Research|October 3, 2017
The IGF-1R/AKT pathway determines cell fate in response to p53Lei Duan, Carl G MakiCancer Drug Resistance (Alhambra, Calif.)|September 17, 2021
P53-regulated autophagy and its impact on drug resistance and cell fateDaeun Shim, Lei Duan, Carl G MakiTranslational Oncology|March 9, 2022
Acetyl-CoA synthetases ACSS1 and ACSS2 are 4-hydroxytamoxifen responsive factors that promote survival in tamoxifen treated and estrogen deprived cellsSarah Calhoun, Lei Duan, Carl G MakiScientific Reports|September 27, 2023
CSE1L is a negative regulator of the RB-DREAM pathway in p53 wild-type NSCLC and can be targeted using an HDAC1/2 inhibitorLei Duan, Mehrdad Jafari Tadi, Carl G MakiIscience|May 6, 2026
Dormancy exit correlates with CREB1 reactivation that is a potential target to overcome endocrine therapy resistance in ER+ breast cancer cellsLei Duan, Kelsey M O'Hara, Carl G MakiCancer Biology & Therapy|October 6, 2018
Alpha ketoglutarate levels, regulated by p53 and OGDH, determine autophagy and cell fate/apoptosis in response to Nutlin-3aLei Duan, Ricardo E Perez, Carl G MakiCancer Letters|July 29, 2014
Critical roles for nitric oxide and ERK in the completion of prosurvival autophagy in 4OHTAM-treated estrogen receptor-positive breast cancer cellsLei Duan, Brian Danzer, Victor V Levenson, et al.Scientific Reports|January 21, 2022
RBL2/DREAM-mediated repression of the Aurora kinase A/B pathway determines therapy responsiveness and outcome in p53 WT NSCLCLei Duan, Ricardo E Perez, Sarah Calhoun, et al.Cancer Biology & Therapy|January 31, 2022
Inhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15Lei Duan, Ricardo E Perez, Sarah Calhoun, et al.Pageof 53